RE:RE:CEO BusyI am not sure if this business trip to Japan has been completed. I am hoping we get some sort of a tweet update regarding how things went. Anything at this point would be encouraging.
They mentioned potential investors which would be very good news. If any large investors step up to the plate that will be bad news for Shiseido and further push them into a settlement with Replicel if they have any hope of marketing RCH-01. Lets hope we see a settlement in early 2023.
With the Dermaprecise Injector so close to being submitted to the FDA for Approval I assume they were interviewing potential distributors for Japan and possble other Asian countries.
RCS-01 and RCT-01 are dependent on a major injection of working capital and bringing Dermaprecise to comercialization. With the dermal injector device approved it will bring much needed revenue to the company as well as it will be used in the next phase of trials for these two stem cell procedures.
I hope I am not too optomistic but I think we are close to "liftoff" for Replicel.